Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 and mFOLFIRINOX in locally advanced pancreatic cancer
NCT03374852Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of devimistat in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Aug 2018; status: withdrawn.
02
Drugs
devimistat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03374852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374852.